P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT

• O. Decaux,
• C. Hulin,
• A. Perrot,
• M. Macro,
• L. Frenzel,
• J. Diels,
• N. J. Perualila,
• F. Ghilotti,
• B. Haefliger,
• E. Goldsztajn,
• S. Vernet,
• J. Thevenon,
• M. Willaime,
• N. Texier,
• J. M. Schecter,
• D. Madduri,
• C. Jackson,
• S. Valluri,
• P. Moreau

Affiliations

O. Decaux

1 Internal medicine and clinical immunology, CHU Rennes, Rennes

C. Hulin

2 Hematology and cell therapy, CHU Bordeaux, Bordeaux

A. Perrot

3 Hematology, Oncopole, Toulouse

M. Macro

4 Hematology, CHU Caen, Caen

L. Frenzel

5 Hematology, Necker-enfants malades hospital, Paris, France

J. Diels

6 Health Economics, Market Access & Reimbursement, Janssen Pharmaceutica NV, Beerse, Belgium

N. J. Perualila

6 Health Economics, Market Access & Reimbursement, Janssen Pharmaceutica NV, Beerse, Belgium

F. Ghilotti

7 Health Economics, Market Access & Reimbursement, Janssen Pharmaceutica NV, Cologno Monzese, Italy

B. Haefliger

8 Health Economics, Market Access & Reimbursement, Cilag GmbH International, Zug, Switzerland

E. Goldsztajn

9 Market Access & Reimbursement

S. Vernet

10 Medical affairs, Janssen, Issy-les-Moulineaux

J. Thevenon

10 Medical affairs, Janssen, Issy-les-Moulineaux

M. Willaime

11 Biometry, Kappa Sante, Paris, France

N. Texier

11 Biometry, Kappa Sante, Paris, France

J. M. Schecter

12 Research and Development, Janssen R&D

D. Madduri

12 Research and Development, Janssen R&D

C. Jackson

12 Research and Development, Janssen R&D

S. Valluri

13 Health Economics, Market Access & Reimbursement, Janssen, Raritan, United States of America

P. Moreau

14 Clinical hematology, University Hospital Hotel-Dieu, Nantes, France